ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by ADMA Biologics, Inc. on March 10, 2023, reporting events that occurred on March 6, 2023. The filing focuses on executive and director compensation decisions approved by the Board of Directors upon the recommendation of the Compensation Committee.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It details specific compensation figures for Named Executive Officers (NEOs) and non-employee directors:
- CEO (Adam S. Grossman): 2023 Base Salary of $750,000; 2022 Cash Bonus of $612,351; 573,695 RSUs; 1,147,385 Stock Options.
- CFO (Brian Lenz): 2023 Base Salary of $475,000; 2022 Cash Bonus of $296,755; 135,175 RSUs; 270,345 Stock Options.
- Stock Option Exercise Price: $3.35 per share (based on March 6, 2023 closing price).
Material Changes and Compensation Policy Updates
The filing reports the following material changes and approvals:
- Executive Compensation: The Board approved 2023 base salaries and 2022 performance-based cash bonuses. The cash bonuses reflect the achievement of 148% of the Company's 2022 corporate goals and milestones.
- Equity Grants: New RSUs and stock options were granted on March 6, 2023. RSUs vest quarterly over four years. Stock options vest 25% after one year and the remaining 75% monthly over the subsequent three years, fully vesting on March 6, 2027.
- Director Compensation Policy: An updated policy effective retroactively to January 1, 2023, was approved. Key terms include:
- Annual cash retainer of $50,000 for non-employee directors.
- Additional fees for Chairman ($40,000) and Vice-Chairman ($40,000).
- Committee chair and member retainers ranging from $5,500 to $22,250.
- Initial equity grant for new directors valued at $350,000 (delivered as options).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors beyond the standard vesting schedules and performance metrics associated with the compensation awards. The compensation awards were determined based on the Compensation Committee's evaluation of performance and consultation with an independent compensation consultant.
Key Facts for Investor Verification
- Verify the 148% achievement of 2022 corporate goals that triggered the executive cash bonuses.
- Confirm the total dilution impact of the 1,756,505 new stock options and 708,870 RSUs granted to the CEO and CFO.
- Review the updated director compensation policy to assess total annual director compensation costs.
- Check the stock price performance relative to the $3.35 exercise price for the newly granted options.